Guardant Health, Inc. (GH)

Guardant Health operates in the precision oncology industry, a sector characterized by rapid technological and scientific breakthroughs, frequent new product introductions, and evolving industry standards. The company is transforming patient care by providing critical insights into what drives disease through advanced blood and tissue tests, real-world data, and AI analytics. The industry is highly competitive, with competition based on price and performance of products, evidence of clinical differentiation, support by key opinion leaders, commercial competitiveness, turnaround time, and scope and quality of payer contracts.

The company faces competition from diagnostic companies offering single-marker or comprehensive genomic profile testing based on next-generation sequencing in either blood or tissue. Competitors within the liquid biopsy space for therapy selection include Foundation Medicine, Inc., Caris Life Sciences, Inc., Tempus AI, Inc., NeoGenomics, Inc., Exact Sciences Corporation, BillionToOne, Inc., Quest Diagnostics, Inc., and Laboratory Corporation of America. In minimal residual disease detection, competitors include Natera, Inc., Tempus AI, Inc., Exact Sciences Corporation, Myriad Genetics, Inc., Caris Life Sciences, Inc., Foundation Medicine, Inc., BillionToOne, Inc., Personalis, Inc., and Quest Diagnostics, Inc. In early screening, competitors include GRAIL, Inc., Exact Sciences Corporation, Freenome Holdings, Inc., Natera, Inc., and Delfi Diagnostics. The company believes its Guardant360 CDx test is the market leading comprehensive liquid biopsy test based on the number of tests ordered.

The company generates revenue primarily from sales of its tests, which accounted for 94% ¹ of revenue in the year ended December 31, 2025, 94% ² in 2024, and 91% ³ in 2023. Revenue is derived from clinical customers in the United States through a targeted sales organization, and from biopharmaceutical companies through a business development team. The company also generates revenue from licensing its digital sequencing technologies to domestic biopharmaceutical customers and international laboratory partners. The company's product portfolio is powered by its Smart Platform, which utilizes methylation technology with genomic, epigenomic, and RNA-based data.

For patients with advanced-stage cancer, the company offers the Guardant360 Liquid test and the Guardant360 CDx test, the first comprehensive liquid biopsy test approved by the FDA to provide tumor mutation profiling with solid tumors and to be used as a companion diagnostic in connection with non-small cell lung cancer, colorectal cancer, and breast cancer. The Guardant360 CDx test is a 74-gene test ⁴ and has been approved by the FDA for use as a companion diagnostic to identify NSCLC patients who may benefit from treatment with TAGRISSO, RYBREVANT, LUMAKRAS, and ENHERTU, breast cancer patients who may benefit from treatment with ORSERDU and INLURIYO, and colorectal cancer patients who may benefit from treatment with BRAFTOVI. The Guardant360 Liquid test measures 740+ genes ⁵ and supports all guideline-recommended biomarkers. The Guardant360 Tissue test is the first molecular profiling test for tumor tissue that incorporates comprehensive multiomics analysis, including DNA, RNA, AI-powered PD-L1, and genome-wide methylation data. For minimal residual disease detection and recurrence monitoring, the company offers the Guardant Reveal test for early-stage colorectal, breast, and lung cancer patients, which has been expanded to include late-stage therapy response monitoring for patients with solid tumors. For early cancer detection, the company offers the Shield blood test for colorectal cancer screening in adults age 45 and older who are at average risk for the disease. Shield is the first blood test approved by the FDA for primary colorectal cancer screening and also the first blood test for colorectal cancer screening that meets coverage requirements by Medicare. The FDA has granted Breakthrough Device designation to the Shield MCD test. For biopharmaceutical customers, the company offers the GuardantINFINITY test, which provides genotyping coverage of more than 800 genes ⁶ with sample-level methylation detection and tumor fraction score, the GuardantOMNI test covering 500 genes ⁷, and the GuardantINFORM platform.

Revenue from the company's top five biopharmaceutical customers, including their affiliated entities, accounted for 11% ⁸ of total revenue in the year ended December 31, 2025, 13% ⁹ in 2024, and 14% ¹⁰ in 2023. Revenue attributable to Medicare accounted for more than 10% ¹¹ of total revenue in each of the years ended December 31, 2025, 2024, and 2023.

In December 2025, the liquid biopsy testing service based on the company's proprietary Guardant360 CDx technology became available at the Policlinico Gemelli facility in Italy following a partnership agreement signed in September 2024. In March 2025, CMS approved ADLT status for the Shield blood test for colorectal cancer screening. In January 2025, Palmetto GBA granted coverage for the Guardant Reveal test to monitor disease recurrence in patients with colorectal cancer in the surveillance setting following curative intent therapy. In May 2025, the coverage for the upgraded Guardant360 Tissue test was expanded by Medicare to include both DNA and RNA testing. In August 2024, following FDA approval, the Shield blood test met the coverage requirements by Medicare based on the criteria established in its National Coverage Determination for blood-based colorectal cancer screening tests, and the test is covered once every three years for eligible Medicare beneficiaries. In March 2025, CMS approved ADLT status for the Shield blood test for colorectal cancer screening. In January 2022, the company received a civil investigative demand from the United States Attorney for the Northern District of California in connection with an investigation under the False Claims Act regarding billing government-funded programs for the Guardant360 test.

For the year ended December 31, 2025, the company incurred a net loss of $416.3 million ¹², compared to a net loss of $436.4 million ¹³ in 2024 and a net loss of $479.4 million ¹⁴ in 2023. As of December 31, 2025, the company had an accumulated deficit of $3.0 billion ¹⁵. The company has incurred significant losses since inception and may continue to incur losses in the future.

A key growth vector is the expansion of the Shield platform into lung cancer screening and multi-cancer detection. The FDA has granted Breakthrough Device designation to the Shield MCD test to provide patients and healthcare providers with timely access to medical devices by speeding up their development, assessment and review. The company has expanded its Shield blood test to include an MCD results report with a data collection effort to better understand the clinical impact of MCD results. The company also expects to expand its MRD portfolio to include a tissue-informed test.

International expansion is a component of the company's long-term growth strategy. The company currently offers tests outside the United States primarily through direct contacts with insurers and hospitals, distributor relationships, and laboratory partnerships. The company has established partnerships with Vall D'Hebron Institute of Oncology in Spain, The Royal Marsden NHS Foundation Trust in the United Kingdom, Fondazione Policlinico Universitario Agostino Gemelli IRCCS in Italy, and Adicon Holdings Limited in China. In Japan, the company received regulatory approval of its Guardant360 CDx test as a companion diagnostic from the MHLW, and in July 2023, the MHLW granted national reimbursement approval for the Guardant360 CDx test for patients with advanced or metastatic solid tumor cancers in Japan.

The filing does not contain specific margin or cost outlook figures.

The filing does not contain a specific operational outlook.

The filing does not contain specific R&D spending levels, capital expenditure plans, share repurchase authorization amounts, or dividend policy figures for the upcoming period.

The company faces structural headwinds related to the variability and unpredictability of the reimbursement landscape. The company estimates the amount of revenue to be recognized at the time a test is provided and records revenue adjustments if and when the cash subsequently received differs from the revenue recorded. Previously recorded revenue adjustments are not indicative of future revenue adjustments from actual cash collections, which may fluctuate significantly. The company has experienced situations where commercial payers proactively reduced the amounts they were willing to reimburse for its tests, and where commercial payers have determined that the amounts previously paid were too high and sought to recover those perceived excess payments by deducting such amounts from payments owed to the company.

The company faces execution risks related to its ability to develop and commercialize new products. The product development process involves a high degree of risk, and product development efforts may fail for many reasons, including failure of the product to perform as expected, lack of validation data, or failure to demonstrate the clinical utility of the product. The company recently migrated some of its existing products to its Smart Platform, and while it believes this platform improves the tests and adds value, the tests may not perform as well as expected on the platform and the market might not accept the value proposition.

Management's message emphasizes the company's objective to be the leading provider of therapy selection, minimal residual disease detection, and early cancer screening products for cancer management across all stages of the disease. The strategic priorities emphasized for the period ahead include increasing awareness of products through building awareness of the product portfolio and developing both blood and tissue testing across all stages of care, employing screening awareness initiatives including through direct-to-consumer channels, educating biopharmaceutical companies, key opinion leaders, and advocacy groups, advocating for inclusion of tests in treatment guidelines, and expanding access to products globally through direct investment and by leveraging a global network of partners. Another priority is expanding clinical utility and increasing reimbursement by working with commercial and government payers to establish coverage and reimbursement, investing in clinical and real-world evidence, demonstrating improved clinical utility and health economics, and pursuing FDA and other regulatory approval internationally. A third priority is strengthening relationships with customers by demonstrating the utility of products in connection with standard of care treatments, developing and seeking approval of products as companion diagnostics, providing earlier insights into emerging clinically relevant biomarkers, providing seamless customer experiences, and expanding lab capabilities and services through partnerships. The company also intends to expand its product portfolio by using its commercial engine and research and development investment to generate data and analytical insights, taking a disciplined and systematic approach to product and market development, utilizing its data, sample biobank and insights into biology of circulating tumor-related biomarkers in blood, building on its regulatory and commercial infrastructure, and using its strategic relationships to drive global commercialization.

For the year ended December 31, 2025, total revenue was not explicitly stated as a single figure in the filing, but the company reported that test revenue accounted for 94% ²¹ of total revenue. Net loss for 2025 was $416.3 million ²², compared to a net loss of $436.4 million ²³ in 2024 and a net loss of $479.4 million ²⁴ in 2023. As of December 31, 2025, the company had an accumulated deficit of $3.0 billion ²⁵. The company did not report diluted EPS or basic EPS figures in the filing text provided. The company's operating results have fluctuated significantly, and the company has historically provided guidance related to annual revenue, non-GAAP gross margin, non-GAAP operating expense, and free cash flow. The company's cash and cash equivalents, marketable securities, and restricted cash balance was not explicitly stated as a single figure in the filing text provided. The company's convertible senior notes due 2027, 2031, and 2033 represent material indebtedness, with the 2027 notes having an initial conversion rate and the 2031 and 2033 notes having specific conversion periods and conditions described in the notes to the financial statements.

The company has incurred significant losses since inception, with net losses of $416.3 million ¹⁶ in 2025, $436.4 million ¹⁷ in 2024, and $479.4 million ¹⁸ in 2023, and an accumulated deficit of $3.0 billion ¹⁹ as of December 31, 2025, and may not be able to generate sufficient revenue to achieve and maintain profitability. The company's revenue is highly dependent on its tests, which accounted for 94% ²⁰ of revenue in 2025, and continued adoption depends on factors including pricing, coverage and reimbursement from third-party payers, clinical data, and inclusion in treatment guidelines. The company relies on a limited number of suppliers, including Illumina as the sole supplier of sequencers and sole provider of maintenance and repair services for these sequencers, and any disruption could materially and adversely impact supply chain and laboratory operations. The company received a civil investigative demand in January 2022 from the United States Attorney for the Northern District of California in connection with an investigation under the False Claims Act regarding billing government-funded programs for the Guardant360 test, and the outcome of this investigation is unpredictable. Changes in FDA enforcement discretion for laboratory developed tests could subject the company's product offerings to more significant regulatory requirements, including premarket review and quality system regulations, which could increase compliance costs and delay test development or commercialization.